CNMD — CONMED CORP
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About CONMED CORP (CNMD)
CONMED CORP (CNMD) appears in the most recent 13F filings of 4 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $26M. Across recent filings, tracked investors recorded 3 new positions, 0 increased, 0 reduced, and 1 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in CNMD
How many top investors track CNMD
A small number of top investors own this.
CNMD Ownership Composition
How CONMED CORP is held across tracked investor types, based on reported 13F positions.
- Other76.3%
- Hedge Funds23.7%
Tracked investors reporting CNMD
- Ken GriffinMar 31, 2026Citadel AdvisorsShares246.9KValue$8.7M% Portfolio0.00%
- Izzy EnglanderMar 31, 2026Millennium ManagementShares175.9KValue$6.2M% Portfolio0.00%
- Steve CohenMar 31, 2026Point72 Asset ManagementShares134.1KValue$4.7M% Portfolio0.01%
- Ray DalioSep 30, 2025Bridgewater AssociatesShares5.9KValue$279K% Portfolio0.00%
Recent activity
- New$5.3MFeb 17, 2026
- New$4.7MMay 15, 2026
- Sold$0(-100.00%)Feb 13, 2026
- New$279KNov 13, 2025
Frequently asked questions
- How many institutional investors hold CNMD?
- 4 tracked institutional investors disclosed a position in CNMD (CONMED CORP) in their most recent 13F filing.
- Who is the largest institutional holder of CNMD?
- Ken Griffin, Citadel Advisors, holds the largest disclosed position in CNMD, valued at $26M.
- Did institutional ownership of CNMD increase or decrease?
- Across recent 13F filings, tracked investors recorded 3 new positions, 0 increased, 0 reduced, and 1 fully exited CNMD.
- Where does this CNMD ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.